Julia Karow
Julia Karow tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb. Follow her on Twitter at @Julia_Karow.

Articles Authored by Julia Karow
Bruker, Illumina, 10x Genomics, Singular Genomics, Scale Bio, and Parse Bio touted better multiplexing, throughput, and multiomics capabilities for their technologies.
While few conference speakers addressed the issue head-on in their scientific presentations, there was rampant chatter in the hallways.

Ultima Genomics Upgrades Sequencer to Serve 'Data-Hungry' Applications, Enable $80 Human Genome
Premium
At the AGBT conference on Tuesday, representatives from the Broad Institute, Labcorp, Johnson & Johnson, and CZI talked about using the UG 100 in various projects.
GenomeWeb caught up with Green on the eve of the AGBT conference, long considered to be the premier gathering for the genomic technology field.

The firm's long-read, single-molecule nanopore sequencer promises low cost and high accuracy for low-throughput applications in research and diagnostics.
The company offered more details on its "constellation" mapped read technology, Illumina Protein Prep assay, 5-base genome, PIPseq V single-cell assay, and paired 500-base MiSeq reads.
ASHG: Herpesvirus Integrated in Human Genome Increases Skin Cancer Risk, UK Biobank Study Finds
Premium
Researchers showed that inherited chromosomally integrated HHV-6 (ici-HHV-6) is associated with a threefold increase in basal cell carcinoma risk.
ASHG President Urges Focus on Penetrance, Expressivity for Genetics-Driven Precision Medicine
In his presidential address, delivered to a packed auditorium on Tuesday, Bruce Gelb acknowledged that this year's event is being somewhat overshadowed by the US presidential election.
The research study, run by Genomics England in collaboration with the UK's National Health Service, plans to sequence the genomes of 100,000 newborns.

German Precision Medicine Model Project Gets Ready for Kickoff as Commercial Providers Cry Foul
The €700 million project will pilot diagnostic genomic testing for cancer and rare diseases for at least five years, but private labs cannot participate.